CCA
MRNA icon

Catalyst Capital Advisors’s Moderna MRNA Stock Holding History

Catalyst Capital Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-301
Closed -$12.5K – 503
2024
Q4 		$12.5K Hold
301
– – ﹤0.01% 472
2024
Q3 		$20.1K Sell
301
-69
-19% -$6.33K ﹤0.01% 450
2024
Q2 		$43.9K Sell
370
-3
-0.8% -$380 ﹤0.01% 257
2024
Q1 		$39.7K Buy
373
+16
+4% +$1.61K ﹤0.01% 263
2023
Q4 		$35.5K Buy
357
+75
+27% +$6.31K ﹤0.01% 242
2023
Q3 		$29.1K Buy
282
+69
+32% +$7.7K ﹤0.01% 284
2023
Q2 		$25.9K Sell
213
-13
-6% -$1.73K ﹤0.01% 295
2023
Q1 		$34.7K Sell
226
-74
-25% -$12.2K ﹤0.01% 263
2022
Q4 		$53.9K Sell
300
-12
-4% -$1.96K ﹤0.01% 252
2022
Q3 		$37K Sell
312
-10,372
-97% -$1.57M ﹤0.01% 276
2022
Q2 		$1.53M Sell
10,684
-221
-2% -$31.6K 0.06% 129
2022
Q1 		$1.88M Buy
10,905
+57
+0.5% +$9.6K 0.08% 133
2021
Q4 		$2.76M Buy
10,848
+10,606
+4,383% +$3.1M 0.13% 110
2021
Q3 		$93K Sell
242
-3
-1% -$1.11K ﹤0.01% 270
2021
Q2 		$58K Buy
245
+8
+3% +$1.43K ﹤0.01% 300
2021
Q1 		$31K Sell
237
-42
-15% -$6.09K ﹤0.01% 300
2020
Q4 		$29K Buy
+279
New +$28.2K ﹤0.01% 294
2019
Q2 		– Sell
-310
Closed -$6K – 453
2019
Q1 		$6K Hold
310
– – ﹤0.01% 345
2018
Q4 		$5K Buy
+310
New +$5.09K ﹤0.01% 362

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Catalyst Capital Advisors's MRNA Position: Q1 2025 in Review

Catalyst Capital Advisors sold out of Moderna (MRNA) in Q1 2025, closing a stake of 301 shares — an estimated $12.5K sold.

Catalyst Capital Advisors first reported a position in MRNA in Q4 2018 and held it in 19 quarters. The position peaked at $2.76M in Q4 2021. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • Catalyst Capital Advisors reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • Catalyst Capital Advisors sold 301 Moderna shares in Q1 2025, an estimated $12.5K.
  • Catalyst Capital Advisors first reported a position in Moderna in Q4 2018 and held it in 19 quarters.
  • Catalyst Capital Advisors's Moderna position peaked at $2.76M in Q4 2021.
  • 693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Catalyst Capital Advisors's 13F filing for Q1 2025, filed 29 Apr 2025.